Asset Management
Compare Stocks
4 / 10Stock Comparison
CNS vs HNNA vs VRTS vs GROW
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
Asset Management
Asset Management - Global
CNS vs HNNA vs VRTS vs GROW — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Asset Management | Asset Management | Asset Management | Asset Management - Global |
| Market Cap | $3.63B | $81M | $949M | $35M |
| Revenue (TTM) | $517M | $36M | $831M | $8M |
| Net Income (TTM) | $164M | $8M | $138M | $98K |
| Gross Margin | 46.8% | 70.1% | 74.9% | 41.7% |
| Operating Margin | 33.4% | 37.0% | 17.4% | -35.3% |
| Forward P/E | 20.8x | 8.0x | 5.5x | — |
| Total Debt | $141M | $41M | $2.84B | $83K |
| Cash & Equiv. | $183M | $72M | $477M | $25M |
CNS vs HNNA vs VRTS vs GROW — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cohen & Steers, Inc. (CNS) | 100 | 111.9 | +11.9% |
| Hennessy Advisors, … (HNNA) | 100 | 127.5 | +27.5% |
| Virtus Investment P… (VRTS) | 100 | 152.5 | +52.5% |
| U.S. Global Investo… (GROW) | 100 | 125.4 | +25.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNS vs HNNA vs VRTS vs GROW
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CNS has the current edge in this matchup, primarily because of its strength in long-term compounding and bank quality.
- 154.3% 10Y total return vs VRTS's 142.6%
- NIM 2.4% vs VRTS's 0.9%
- Efficiency ratio 0.1% vs GROW's 0.8% (lower = leaner)
- Efficiency ratio 0.1% vs GROW's 0.8%
HNNA is the #2 pick in this set and the best alternative if growth exposure and defensive is your priority.
- Rev growth 19.9%, EPS growth 38.0%
- Beta 0.30, yield 5.3%, current ratio 12.72x
- 19.9% NII/revenue growth vs GROW's -23.1%
- Beta 0.30 vs VRTS's 1.14, lower leverage
VRTS is the clearest fit if your priority is income & stability and valuation efficiency.
- Dividend streak 7 yrs, beta 1.14, yield 6.6%
- PEG 0.38 vs CNS's 16.52
- Lower P/E (5.5x vs 20.8x), PEG 0.38 vs 16.52
- 6.6% yield, 7-year raise streak, vs CNS's 3.3%
GROW is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.71, Low D/E 0.2%, current ratio 20.87x
- +27.8% vs VRTS's -5.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.9% NII/revenue growth vs GROW's -23.1% | |
| Value | Lower P/E (5.5x vs 20.8x), PEG 0.38 vs 16.52 | |
| Quality / Margins | Efficiency ratio 0.1% vs GROW's 0.8% (lower = leaner) | |
| Stability / Safety | Beta 0.30 vs VRTS's 1.14, lower leverage | |
| Dividends | 6.6% yield, 7-year raise streak, vs CNS's 3.3% | |
| Momentum (1Y) | +27.8% vs VRTS's -5.5% | |
| Efficiency (ROA) | Efficiency ratio 0.1% vs GROW's 0.8% |
CNS vs HNNA vs VRTS vs GROW — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CNS vs HNNA vs VRTS vs GROW — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
VRTS leads in 2 of 6 categories
CNS leads 1 • HNNA leads 1 • GROW leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — HNNA and VRTS each lead in 2 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
VRTS is the larger business by revenue, generating $831M annually — 98.3x GROW's $8M. CNS is the more profitable business, keeping 29.2% of every revenue dollar as net income compared to GROW's -4.0%.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $517M | $36M | $831M | $8M |
| EBITDAEarnings before interest/tax | $198M | $11M | $205M | -$2M |
| Net IncomeAfter-tax profit | $164M | $8M | $138M | $98,000 |
| Free Cash FlowCash after capex | -$94M | $10M | -$67M | -$235,000 |
| Gross MarginGross profit ÷ Revenue | +46.8% | +70.1% | +74.9% | +41.7% |
| Operating MarginEBIT ÷ Revenue | +33.4% | +37.0% | +17.4% | -35.3% |
| Net MarginNet income ÷ Revenue | +29.2% | +28.0% | +16.7% | -4.0% |
| FCF MarginFCF ÷ Revenue | +16.4% | +37.6% | -8.9% | -9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +5.2% | -27.3% | +10.9% | — |
Valuation Metrics
VRTS leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 7.1x trailing earnings, VRTS trades at a 70% valuation discount to CNS's 23.9x P/E. Adjusting for growth (PEG ratio), VRTS offers better value at 0.48x vs CNS's 19.03x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $3.6B | $81M | $949M | $35M |
| Enterprise ValueMkt cap + debt − cash | $3.6B | $49M | $3.3B | $10M |
| Trailing P/EPrice ÷ TTM EPS | 23.94x | 8.03x | 7.10x | -104.80x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.79x | — | 5.55x | — |
| PEG RatioP/E ÷ EPS growth rate | 19.03x | 2.18x | 0.48x | — |
| EV / EBITDAEnterprise value multiple | 19.48x | 3.62x | 16.20x | — |
| Price / SalesMarket cap ÷ Revenue | 7.01x | 2.27x | 1.14x | 4.14x |
| Price / BookPrice ÷ Book value/share | 6.30x | 0.82x | 0.95x | 0.77x |
| Price / FCFMarket cap ÷ FCF | 42.64x | 6.03x | — | — |
Profitability & Efficiency
CNS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
CNS delivers a 28.3% return on equity — every $100 of shareholder capital generates $28 in annual profit, vs $0 for GROW. GROW carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to VRTS's 2.74x. On the Piotroski fundamental quality scale (0–9), HNNA scores 7/9 vs GROW's 2/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +28.3% | +8.5% | +13.5% | +0.2% |
| ROA (TTM)Return on assets | +20.5% | +5.3% | +3.6% | +0.2% |
| ROICReturn on invested capital | +19.2% | +7.3% | +3.0% | -4.7% |
| ROCEReturn on capital employed | +22.8% | +8.7% | +3.7% | -6.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 5 | 2 |
| Debt / EquityFinancial leverage | 0.25x | 0.41x | 2.74x | 0.00x |
| Net DebtTotal debt minus cash | -$42M | -$32M | $2.4B | -$24M |
| Cash & Equiv.Liquid assets | $183M | $72M | $477M | $25M |
| Total DebtShort + long-term debt | $141M | $41M | $2.8B | $83,000 |
| Interest CoverageEBIT ÷ Interest expense | — | 9.62x | 2.15x | 600.00x |
Total Returns (Dividends Reinvested)
HNNA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HNNA five years ago would be worth $13,761 today (with dividends reinvested), compared to $4,143 for GROW. Over the past 12 months, GROW leads with a +27.8% total return vs VRTS's -5.5%. The 3-year compound annual growth rate (CAGR) favors HNNA at 18.6% vs VRTS's 0.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +12.9% | +7.4% | -9.8% | +7.7% |
| 1-Year ReturnPast 12 months | -5.2% | +1.2% | -5.5% | +27.8% |
| 3-Year ReturnCumulative with dividends | +44.3% | +66.8% | +0.1% | +3.3% |
| 5-Year ReturnCumulative with dividends | +18.2% | +37.6% | -35.0% | -58.6% |
| 10-Year ReturnCumulative with dividends | +154.3% | -35.0% | +142.6% | +67.4% |
| CAGR (3Y)Annualised 3-year return | +13.0% | +18.6% | +0.0% | +1.1% |
Risk & Volatility
Evenly matched — CNS and HNNA each lead in 1 of 2 comparable metrics.
Risk & Volatility
HNNA is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than VRTS's 1.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CNS currently trades 84.7% from its 52-week high vs VRTS's 65.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 0.30x | 1.14x | 0.71x |
| 52-Week HighHighest price in past year | $83.99 | $13.19 | $215.06 | $3.65 |
| 52-Week LowLowest price in past year | $58.39 | $8.90 | $121.61 | $2.10 |
| % of 52W HighCurrent price vs 52-week peak | +84.7% | +77.3% | +65.9% | +71.8% |
| RSI (14)Momentum oscillator 0–100 | 63.1 | 51.6 | 55.4 | 46.5 |
| Avg Volume (50D)Average daily shares traded | 323K | 9K | 101K | 25K |
Analyst Outlook
VRTS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CNS as "Sell", VRTS as "Hold". Consensus price targets imply 15.0% upside for VRTS (target: $163) vs 6.9% for CNS (target: $76). For income investors, VRTS offers the higher dividend yield at 6.58% vs CNS's 3.29%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Sell | — | Hold | — |
| Price TargetConsensus 12-month target | $76.00 | — | $163.00 | — |
| # AnalystsCovering analysts | 13 | — | 11 | — |
| Dividend YieldAnnual dividend ÷ price | +3.3% | +5.3% | +6.6% | +3.5% |
| Dividend StreakConsecutive years of raises | 2 | 1 | 7 | 1 |
| Dividend / ShareAnnual DPS | $2.34 | $0.54 | $9.32 | $0.09 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +0.6% | +6.3% | +5.6% |
VRTS leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). CNS leads in 1 (Profitability & Efficiency). 2 tied.
CNS vs HNNA vs VRTS vs GROW: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CNS or HNNA or VRTS or GROW a better buy right now?
For growth investors, Hennessy Advisors, Inc.
(HNNA) is the stronger pick with 19. 9% revenue growth year-over-year, versus -23. 1% for U. S. Global Investors, Inc. (GROW). Virtus Investment Partners, Inc. (VRTS) offers the better valuation at 7. 1x trailing P/E (5. 5x forward), making it the more compelling value choice. Analysts rate Virtus Investment Partners, Inc. (VRTS) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CNS or HNNA or VRTS or GROW?
On trailing P/E, Virtus Investment Partners, Inc.
(VRTS) is the cheapest at 7. 1x versus Cohen & Steers, Inc. at 23. 9x. On forward P/E, Virtus Investment Partners, Inc. is actually cheaper at 5. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Virtus Investment Partners, Inc. wins at 0. 38x versus Cohen & Steers, Inc. 's 16. 52x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CNS or HNNA or VRTS or GROW?
Over the past 5 years, Hennessy Advisors, Inc.
(HNNA) delivered a total return of +37. 6%, compared to -58. 6% for U. S. Global Investors, Inc. (GROW). Over 10 years, the gap is even starker: CNS returned +154. 3% versus HNNA's -35. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CNS or HNNA or VRTS or GROW?
By beta (market sensitivity over 5 years), Hennessy Advisors, Inc.
(HNNA) is the lower-risk stock at 0. 30β versus Virtus Investment Partners, Inc. 's 1. 14β — meaning VRTS is approximately 275% more volatile than HNNA relative to the S&P 500. On balance sheet safety, U. S. Global Investors, Inc. (GROW) carries a lower debt/equity ratio of 0% versus 3% for Virtus Investment Partners, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CNS or HNNA or VRTS or GROW?
By revenue growth (latest reported year), Hennessy Advisors, Inc.
(HNNA) is pulling ahead at 19. 9% versus -23. 1% for U. S. Global Investors, Inc. (GROW). On earnings-per-share growth, the picture is similar: Hennessy Advisors, Inc. grew EPS 38. 0% year-over-year, compared to -126. 6% for U. S. Global Investors, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CNS or HNNA or VRTS or GROW?
Cohen & Steers, Inc.
(CNS) is the more profitable company, earning 29. 2% net margin versus -4. 0% for U. S. Global Investors, Inc. — meaning it keeps 29. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HNNA leads at 37. 0% versus -35. 3% for GROW. At the gross margin level — before operating expenses — VRTS leads at 74. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CNS or HNNA or VRTS or GROW more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Virtus Investment Partners, Inc. (VRTS) is the more undervalued stock at a PEG of 0. 38x versus Cohen & Steers, Inc. 's 16. 52x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Virtus Investment Partners, Inc. (VRTS) trades at 5. 5x forward P/E versus 20. 8x for Cohen & Steers, Inc. — 15. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRTS: 15. 0% to $163. 00.
08Which pays a better dividend — CNS or HNNA or VRTS or GROW?
All stocks in this comparison pay dividends.
Virtus Investment Partners, Inc. (VRTS) offers the highest yield at 6. 6%, versus 3. 3% for Cohen & Steers, Inc. (CNS).
09Is CNS or HNNA or VRTS or GROW better for a retirement portfolio?
For long-horizon retirement investors, Hennessy Advisors, Inc.
(HNNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 30), 5. 3% yield). Both have compounded well over 10 years (HNNA: -35. 0%, VRTS: +142. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CNS and HNNA and VRTS and GROW?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CNS is a small-cap income-oriented stock; HNNA is a small-cap high-growth stock; VRTS is a small-cap deep-value stock; GROW is a small-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.